CTI BioPharma Corp. (CTIC) said Monday it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. The company expects to report topline data from the trial by the end of 2020.
from RTT - Biotech https://ift.tt/2Bgs3Yg
via IFTTT
No comments:
Post a Comment